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reported, from the perspective of a large national referral
centre, an impressive discriminatory capacity for sweat
conductivity in the diagnosis of cystic fibrosis. They and
others [2] have suggested that further experience of its use is
reported across a range of clinical settings before consider-
ing it as a definitive diagnostic test. Furthermore, evidence-
based guidelines, produced by a multidisciplinary working
group supported by the Cystic Fibrosis Trust, and appraised
by the Royal College of Paediatrics and Child Health in the
United Kingdom, have emphasised the importance of con-
tinued measurement of sweat chloride as an essential analyte
until the relative merits of conductivity have been estab-
lished [3].
We wish to contribute to this debate by describing our
own experience from a large, non-specialist district hospital
serving a total of about 100,000 children 0–16 years (total
managed population 450,000), with a cystic fibrosis popu-
lation of 60 (38 children, 22 adults). In our service, about 60
sweat tests are performed annually by 3 senior nurses in our
Children’s Daycare Unit. We use the Macroduct sweat
collection system (Wescor), with near patient conductivity
testing using a 3100 Sweat-Chek conductivity analyser
(Wescor), and laboratory chloride estimation on the same
sample. The methodology for collection, equipment calibra-
tion and sample analysis is essentially the same as reported
by Lezana et al. [1].
During the period January 1996–December 2001, 387
patients (386 children, 1 adult) attended for sweat testing.
Sweat conductivity was successfully estimated in 343 (89%)
samples, of which 242 (71%) gave an adequate sample size
(30 Al) for laboratory chloride analysis. Cystic fibrosis was
diagnosed in 16 patients (1 adult, 15 children) on the basis
of at least 1 sweat chloride of greater than 60 mmol/l with a
recognised cystic fibrosis genotype (15 patients), or 2
abnormal sweat chloride results with unknown genotype
(1 patient).
For the analysis of our results, a cut-off value for sweat
conductivity of 90 mmol/l (equivalent NaCl) was used as
suggested by Lezana et al. We found one cystic fibrosis
patient with a conductivity less than this (value 85) and no
non-cystic fibrosis subjects with values over 90, giving a1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.06.003sensitivity for the test of 94% and specificity of 100% (95%
lower confidence limits 72% and 98%, respectively). The
positive predictive value was 100%, the negative predictive
value 99.6%.
Our results confirm the applicability of near patient
conductivity testing in a district hospital setting. In our
experience, the immediate availability of results was both
clinically useful for planning further investigation and
management, and much appreciated by subjects and their
parents. Our success rates for conductivity measurement,
and laboratory chloride measurement on the same sample,
are comparable with those obtained in larger and more
specialist units [1,2], but demonstrate that repeat sweat
collection is necessary in a significant number of patients if
sweat chloride is deemed an essential analyte. The rela-
tively small number of subjects in our study, particularly
those with cystic fibrosis, means that our results lack the
statistical power to indicate that conductivity measurement
alone can replace laboratory chloride estimation for the
diagnosis of cystic fibrosis. However, they support the
suggestion of Lezana et al. that conductivity might be as
reliable as quantitative sweat chloride measurement for the
diagnosis and exclusion of cystic fibrosis, particularly when
combined with genotype analysis for patients with results
in the borderline range. Further published experience of
sweat conductivity from non-specialist district hospitals is
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